Rezolute, Inc.

What is Tumor Hyperinsulinism (HI)? ?? Tumor HI is a rare disease in which a tumor overproduces insulin or insulin-like substances causing severe hypoglycemia, which can be life-threatening. Years of misdiagnosis and poor management have left patients to deal with the consequences of hypoglycemia, which can include seizures and brain damage, and the inability to receive tumor-directed therapies. Here's how RZ358 (ersodetug) can help ??♂? An antibody designed to treat all forms of HI that has received FDA clearance for a Phase 3 registrational study in tumor HI patients based on real-world benefit already demonstrated in patients on a compassionate use basis. Learn more about the promising findings in The New England Journal of Medicine: https://bit.ly/3YKgpvP #hyperinsulinism #hypoglycemia #raredisease #cancer

We're #hiring! Learn more about Rezolute and check out new opportunities to join our rapidly growing team: https://lnkd.in/ecAZetUr

Today is World Neuroendocrine Cancer Day. Together, we can help support individuals impacted by neuroendocrine tumors (NETs), a group of rare cancers that develop in hormone-producing cells across the body, including the pancreas, and are frequently misdiagnosed. NETs, like many other tumors, can overproduce insulin or insulin-like substances, leading to tumor hyperinsulinism (HI) and severe hypoglycemia. If left untreated, tumor HI can significantly impact quality of life and the ability to receive tumor-directed therapies. Learn the signs and symptoms of NETs to encourage earlier diagnosis and awareness: https://lnkd.in/gYuPmfcZ Together, we can make a difference! ?? #NETCancerDay #RareDisease #CancerAwareness #letstalkaboutnets #cancer

We look forward to participating in the upcoming Guggenheim Securities and Jefferies healthcare conferences taking place this month. Make sure to contact your respective representatives to meet with the Rezolute management team! https://bit.ly/3NXGmTN

The Rezolute team had a great time at the 15th Annual German Family Conference hosted by Kongenitaler Hyperinsulinismus, eV last week in Berlin! We are grateful to the organizers for giving us the opportunity to meet with families, hear their stories, and share our novel approach to a potential treatment for #cHI.? #sunRIZE #hyperinsulinism #hypoglycemia #raredisease

As #HypoglycemiaAwarenessWeek comes to a close, Rezolute would like to shine a spotlight on the outstanding work our partner patient advocacies do each and every day to support patients and families living with #CongenitalHyperinsulinism. congenitalhi.org hyperinsulinism.co.uk https://lnkd.in/e3Ev92za hyperinsulinismus.de #hypoglycemia #clinicaltrials #raredisease

Compassionate use programs play a crucial, yet often underappreciated, role in drug development; providing patients, particularly those with rare diseases, access to potentially life-saving therapies that may positively impact the trajectory of their health outcomes. ? We're thrilled to publish, in partnership with WEP Clinical and Ana Paula Tediosi, this two-part series on compassionate use programs and the meaningful benefits in the development of a potential treatment for multiple forms of insulin receptor mediated hypoglycemia. https://bit.ly/4eXiL0O #clinicaltrials #clinicalresearch #raredisease #hypoglycemiaawarenessweek

Interested in cutting edge science for treating rare disease at a company with two late-stage programs? Check out this role and other opportunities to join our growing team! https://lnkd.in/ecAZetUr

Today we reported our Q4 and full year fiscal 2024 financial results. Learn more about recent progress and plans to advance our antibody therapy, RZ358 (ersodetug), in two Phase 3 trials for the treatment of hypoglycemia resulting from congenital and acquired forms of hyperinsulinism: https://bit.ly/4e7BQ0w

Tomorrow, Dr. Arshad M. Khanani will be presenting "Results from the Phase 2a study of a novel, orally administered Plasma Kallikrein Inhibitor in patients with Diabetic Macular Edema (DME)" at the European Society of Retina Specialists (EURETINA). Learn more about our novel PKIs and unique approach to DME.